Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: Results from the prostate cancer prevention trial

Marian L. Neuhouser, Elizabeth A Platz, Cathee Till, Catherine M. Tangen, Phyllis J. Goodman, Alan Kristal, Howard L. Parnes, Yuzhen Tao, William D. Figg, M. Scott Lucia, Ashraful Hoque, Ann W. Hsing, Ian M. Thompson, Michael Pollak

Research output: Contribution to journalArticle

Abstract

The role of the insulin-like growth factor (IGF) axis and whether IGFs interact with androgensuppressing agents in relation to prostate carcinogenesis is unclear. This nested case-control study (n = 1,652 cases/1,543 controls) examined whether serum IGF1, IGF2, IGFBP2, IGFBP3, and the IGF1: IGFBP3 ratio were associated with prostate cancer in the Prostate Cancer Prevention Trial (PCPT), a randomized, placebo-controlled trial of finasteride for prostate cancer prevention. Presence or absence of cancer was determined by prostate biopsy. Baseline serum was assayed for IGF-axis analytes using ELISA. Logistic regression estimated ORs and 95% confidence intervals for risk of total, low-grade (Gleason 2-6) and high-grade (Gleason 7-10) cancers. Results were stratified by intervention assignment. In both the placebo and finasteride arms, serum IGF1, IGF2, IGFBP3, and the IGF1:IGFBP3 ratio were not associated with prostate cancer. However, men in the highest versus lowest quartile of serum IGFBP2 had a 48% (Ptrend = 0.02) and 55% (Ptrend = 0.01) increased risk for total and low-grade cancers, respectively. These IGFBP2 associations were attenuated and no longer statistically significant in the finasteride arm. Our results suggest that in general, serum IGF-axis analytes were not associated with prostate cancer risk in the PCPT in which presence or absence of all cancers was biopsy-determined. The exception was the finding that high serum IGFBP2 is a risk factor for low-grade disease, which was attenuated for men on finasteride. Further research is needed to understand better the risk incurred by high IGFBP2 and whether androgen-suppressing agents such as finasteride influence aspects of IGFBP2 physiology relevant to prostate carcinogenesis.

Original languageEnglish (US)
Pages (from-to)91-99
Number of pages9
JournalCancer Prevention Research
Volume6
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Insulin-Like Growth Factor Binding Proteins
Somatomedins
Finasteride
Prostatic Neoplasms
Serum
Prostate
Neoplasms
Carcinogenesis
Placebos
Biopsy
Androgens
Case-Control Studies
Randomized Controlled Trials
Logistic Models
Enzyme-Linked Immunosorbent Assay
Confidence Intervals
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk : Results from the prostate cancer prevention trial. / Neuhouser, Marian L.; Platz, Elizabeth A; Till, Cathee; Tangen, Catherine M.; Goodman, Phyllis J.; Kristal, Alan; Parnes, Howard L.; Tao, Yuzhen; Figg, William D.; Lucia, M. Scott; Hoque, Ashraful; Hsing, Ann W.; Thompson, Ian M.; Pollak, Michael.

In: Cancer Prevention Research, Vol. 6, No. 2, 02.2013, p. 91-99.

Research output: Contribution to journalArticle

Neuhouser, ML, Platz, EA, Till, C, Tangen, CM, Goodman, PJ, Kristal, A, Parnes, HL, Tao, Y, Figg, WD, Lucia, MS, Hoque, A, Hsing, AW, Thompson, IM & Pollak, M 2013, 'Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: Results from the prostate cancer prevention trial', Cancer Prevention Research, vol. 6, no. 2, pp. 91-99. https://doi.org/10.1158/1940-6207.CAPR-12-0250
Neuhouser, Marian L. ; Platz, Elizabeth A ; Till, Cathee ; Tangen, Catherine M. ; Goodman, Phyllis J. ; Kristal, Alan ; Parnes, Howard L. ; Tao, Yuzhen ; Figg, William D. ; Lucia, M. Scott ; Hoque, Ashraful ; Hsing, Ann W. ; Thompson, Ian M. ; Pollak, Michael. / Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk : Results from the prostate cancer prevention trial. In: Cancer Prevention Research. 2013 ; Vol. 6, No. 2. pp. 91-99.
@article{72cf5931e02d42b8874a690e3b0828a9,
title = "Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: Results from the prostate cancer prevention trial",
abstract = "The role of the insulin-like growth factor (IGF) axis and whether IGFs interact with androgensuppressing agents in relation to prostate carcinogenesis is unclear. This nested case-control study (n = 1,652 cases/1,543 controls) examined whether serum IGF1, IGF2, IGFBP2, IGFBP3, and the IGF1: IGFBP3 ratio were associated with prostate cancer in the Prostate Cancer Prevention Trial (PCPT), a randomized, placebo-controlled trial of finasteride for prostate cancer prevention. Presence or absence of cancer was determined by prostate biopsy. Baseline serum was assayed for IGF-axis analytes using ELISA. Logistic regression estimated ORs and 95{\%} confidence intervals for risk of total, low-grade (Gleason 2-6) and high-grade (Gleason 7-10) cancers. Results were stratified by intervention assignment. In both the placebo and finasteride arms, serum IGF1, IGF2, IGFBP3, and the IGF1:IGFBP3 ratio were not associated with prostate cancer. However, men in the highest versus lowest quartile of serum IGFBP2 had a 48{\%} (Ptrend = 0.02) and 55{\%} (Ptrend = 0.01) increased risk for total and low-grade cancers, respectively. These IGFBP2 associations were attenuated and no longer statistically significant in the finasteride arm. Our results suggest that in general, serum IGF-axis analytes were not associated with prostate cancer risk in the PCPT in which presence or absence of all cancers was biopsy-determined. The exception was the finding that high serum IGFBP2 is a risk factor for low-grade disease, which was attenuated for men on finasteride. Further research is needed to understand better the risk incurred by high IGFBP2 and whether androgen-suppressing agents such as finasteride influence aspects of IGFBP2 physiology relevant to prostate carcinogenesis.",
author = "Neuhouser, {Marian L.} and Platz, {Elizabeth A} and Cathee Till and Tangen, {Catherine M.} and Goodman, {Phyllis J.} and Alan Kristal and Parnes, {Howard L.} and Yuzhen Tao and Figg, {William D.} and Lucia, {M. Scott} and Ashraful Hoque and Hsing, {Ann W.} and Thompson, {Ian M.} and Michael Pollak",
year = "2013",
month = "2",
doi = "10.1158/1940-6207.CAPR-12-0250",
language = "English (US)",
volume = "6",
pages = "91--99",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk

T2 - Results from the prostate cancer prevention trial

AU - Neuhouser, Marian L.

AU - Platz, Elizabeth A

AU - Till, Cathee

AU - Tangen, Catherine M.

AU - Goodman, Phyllis J.

AU - Kristal, Alan

AU - Parnes, Howard L.

AU - Tao, Yuzhen

AU - Figg, William D.

AU - Lucia, M. Scott

AU - Hoque, Ashraful

AU - Hsing, Ann W.

AU - Thompson, Ian M.

AU - Pollak, Michael

PY - 2013/2

Y1 - 2013/2

N2 - The role of the insulin-like growth factor (IGF) axis and whether IGFs interact with androgensuppressing agents in relation to prostate carcinogenesis is unclear. This nested case-control study (n = 1,652 cases/1,543 controls) examined whether serum IGF1, IGF2, IGFBP2, IGFBP3, and the IGF1: IGFBP3 ratio were associated with prostate cancer in the Prostate Cancer Prevention Trial (PCPT), a randomized, placebo-controlled trial of finasteride for prostate cancer prevention. Presence or absence of cancer was determined by prostate biopsy. Baseline serum was assayed for IGF-axis analytes using ELISA. Logistic regression estimated ORs and 95% confidence intervals for risk of total, low-grade (Gleason 2-6) and high-grade (Gleason 7-10) cancers. Results were stratified by intervention assignment. In both the placebo and finasteride arms, serum IGF1, IGF2, IGFBP3, and the IGF1:IGFBP3 ratio were not associated with prostate cancer. However, men in the highest versus lowest quartile of serum IGFBP2 had a 48% (Ptrend = 0.02) and 55% (Ptrend = 0.01) increased risk for total and low-grade cancers, respectively. These IGFBP2 associations were attenuated and no longer statistically significant in the finasteride arm. Our results suggest that in general, serum IGF-axis analytes were not associated with prostate cancer risk in the PCPT in which presence or absence of all cancers was biopsy-determined. The exception was the finding that high serum IGFBP2 is a risk factor for low-grade disease, which was attenuated for men on finasteride. Further research is needed to understand better the risk incurred by high IGFBP2 and whether androgen-suppressing agents such as finasteride influence aspects of IGFBP2 physiology relevant to prostate carcinogenesis.

AB - The role of the insulin-like growth factor (IGF) axis and whether IGFs interact with androgensuppressing agents in relation to prostate carcinogenesis is unclear. This nested case-control study (n = 1,652 cases/1,543 controls) examined whether serum IGF1, IGF2, IGFBP2, IGFBP3, and the IGF1: IGFBP3 ratio were associated with prostate cancer in the Prostate Cancer Prevention Trial (PCPT), a randomized, placebo-controlled trial of finasteride for prostate cancer prevention. Presence or absence of cancer was determined by prostate biopsy. Baseline serum was assayed for IGF-axis analytes using ELISA. Logistic regression estimated ORs and 95% confidence intervals for risk of total, low-grade (Gleason 2-6) and high-grade (Gleason 7-10) cancers. Results were stratified by intervention assignment. In both the placebo and finasteride arms, serum IGF1, IGF2, IGFBP3, and the IGF1:IGFBP3 ratio were not associated with prostate cancer. However, men in the highest versus lowest quartile of serum IGFBP2 had a 48% (Ptrend = 0.02) and 55% (Ptrend = 0.01) increased risk for total and low-grade cancers, respectively. These IGFBP2 associations were attenuated and no longer statistically significant in the finasteride arm. Our results suggest that in general, serum IGF-axis analytes were not associated with prostate cancer risk in the PCPT in which presence or absence of all cancers was biopsy-determined. The exception was the finding that high serum IGFBP2 is a risk factor for low-grade disease, which was attenuated for men on finasteride. Further research is needed to understand better the risk incurred by high IGFBP2 and whether androgen-suppressing agents such as finasteride influence aspects of IGFBP2 physiology relevant to prostate carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84874496227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874496227&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-12-0250

DO - 10.1158/1940-6207.CAPR-12-0250

M3 - Article

C2 - 23315596

AN - SCOPUS:84874496227

VL - 6

SP - 91

EP - 99

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 2

ER -